Non-surgical Treatment of Peri-implant Pockets With H42

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age25-65
SponsorBioteck S.p.A.

About this trial

This prospective, observational study evaluates the efficacy and safety of H42 non-surgical treatment for peri-implant pockets. The trial involves 56 patients, with 28 subjects receiving the H42 treatment and 28 acting as a control group to monitor soft tissue healing and bone level changes.

Clinical outcomes focus on Pocket Probing Depth (PPD) and Silness and Löe Plaque Index (PI) measured at baseline, 1 month, and 3 months. Gingival inflammation, pain intensity on a 0-10 NRS scale, and absence of infection are monitored at baseline, 7, 14, and 21 days, and at 1 and 3 months. Additionally, a five-point tissue assessment evaluates color, suppuration, granulation tissue, bleeding, and incision margins. Radiographic analysis at baseline and 3 months uses standardized periapical x-rays to measure bone level, intra-bony defect height, width, and angulation. Safety is assessed through the continuous registration of adverse events.

Eligibility criteria

Qualifiers

Men or women with age ≥ 25 and ≤ 65 years.

Subjects affected by peri-implant pockets with probing depth (PD) in the range between 6 to 8 mm.

Each subject can have from 1 to 5 defects.

Subjects willing to provide signed informed consent to clinical investigation participation.

Disqualifiers

Use of aspirin and antiplatelet agents a week before treatment.

Subjects smokers ≥ 10 cigarettes per day.

Subjects presenting current or previous bleeding disorders.

Subjects taking or having indications for anticoagulant therapy.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

56 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Bioteck S.p.A.

Lead sponsor

University of Seville

Collaborator